Resistance mechanisms to osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), have been a major challenge in the treatment of non-small cell lung cancer (NSCLC). Osimertinib is highly effective in patients with EGFR-positive NSCLC, but the development of resistance limits its long-term efficacy.
Several resistance mechanisms to osimertinib have been identified. The most common mechanism is the acquisition of secondary mutations in the EGFR gene, particularly the EGFR T790M mutation. This mutation prevents osimertinib from binding to the EGFR protein, leading to treatment failure. Other resistance mechanisms include amplification of the MET oncogene, activation of bypass signaling pathways such as HER2 and AXL, and histological transformation to small cell lung cancer.
To overcome osimertinib resistance, several therapeutic strategies are being explored. One approach is the development of next-generation TKIs that can target the T790M mutation and other resistant mutations. For example, rociletinib and olmutinib have shown promising results in early clinical trials. Another strategy is the combination of osimertinib with other targeted agents, such as MET inhibitors or HER2 inhibitors, to overcome bypass signaling pathways. Additionally, immunotherapy agents like programmed death-1 (PD-1) inhibitors are being investigated in combination with osimertinib to enhance anti-tumor immune response.
Furthermore, novel treatment approaches are being explored to target specific resistance mechanisms. For instance, combination therapies that simultaneously target multiple resistance mechanisms are being tested. Additionally, strategies to prevent the emergence of resistance, such as intermittent dosing and maintenance therapy, are also being investigated.
In conclusion, resistance to osimertinib remains a significant challenge in the treatment of NSCLC. Understanding the underlying resistance mechanisms and developing novel therapeutic strategies are crucial to improve long-term outcomes for patients with EGFR-positive NSCLC. |
求助已关闭
30